Protagonist Therapeutics Inc
Research Protagonist Therapeutics Inc (PTGX) on Bullrun: market cap USD 7.82B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPTGX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 7.82B
- Financial periodFY2025
- RevenueUSD 46.02M
- Revenue growth-89.4%
- Net income-USD 130.15M
- Free cash flowUSD 56.08M
Valuation Snapshot
latest market cap is USD 7.82B.
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
Frequently asked questions
What is Protagonist Therapeutics Inc's market cap?
Protagonist Therapeutics Inc's market capitalization is USD 7.82B.
What does Protagonist Therapeutics Inc do?
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis;